Bausch + Lomb (BLCO) Competitors $13.51 +0.77 (+6.05%) As of 01:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BLCO vs. SNN, SOLV, PEN, STVN, GKOS, NARI, INSP, SLNO, IRTC, and TMDXShould you be buying Bausch + Lomb stock or one of its competitors? The main competitors of Bausch + Lomb include Smith & Nephew (SNN), Solventum (SOLV), Penumbra (PEN), Stevanato Group (STVN), Glaukos (GKOS), Inari Medical (NARI), Inspire Medical Systems (INSP), Soleno Therapeutics (SLNO), iRhythm Technologies (IRTC), and TransMedics Group (TMDX). These companies are all part of the "medical equipment" industry. Bausch + Lomb vs. Smith & Nephew Solventum Penumbra Stevanato Group Glaukos Inari Medical Inspire Medical Systems Soleno Therapeutics iRhythm Technologies TransMedics Group Smith & Nephew (NYSE:SNN) and Bausch + Lomb (NYSE:BLCO) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, community ranking, dividends, risk and analyst recommendations. Do analysts recommend SNN or BLCO? Smith & Nephew presently has a consensus target price of $27.00, indicating a potential upside of 0.84%. Bausch + Lomb has a consensus target price of $18.82, indicating a potential upside of 40.49%. Given Bausch + Lomb's stronger consensus rating and higher probable upside, analysts plainly believe Bausch + Lomb is more favorable than Smith & Nephew.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Smith & Nephew 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Bausch + Lomb 1 Sell rating(s) 7 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.25 Is SNN or BLCO more profitable? Smith & Nephew has a net margin of 0.00% compared to Bausch + Lomb's net margin of -6.62%. Bausch + Lomb's return on equity of 3.35% beat Smith & Nephew's return on equity.Company Net Margins Return on Equity Return on Assets Smith & NephewN/A N/A N/A Bausch + Lomb -6.62%3.35%1.66% Does the MarketBeat Community favor SNN or BLCO? Smith & Nephew received 410 more outperform votes than Bausch + Lomb when rated by MarketBeat users. Likewise, 54.29% of users gave Smith & Nephew an outperform vote while only 41.49% of users gave Bausch + Lomb an outperform vote. CompanyUnderperformOutperformSmith & NephewOutperform Votes44954.29% Underperform Votes37845.71% Bausch + LombOutperform Votes3941.49% Underperform Votes5558.51% Do insiders and institutionals have more ownership in SNN or BLCO? 25.6% of Smith & Nephew shares are owned by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are owned by institutional investors. 1.0% of Smith & Nephew shares are owned by company insiders. Comparatively, 0.2% of Bausch + Lomb shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more risk & volatility, SNN or BLCO? Smith & Nephew has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Comparatively, Bausch + Lomb has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500. Which has better valuation and earnings, SNN or BLCO? Smith & Nephew has higher revenue and earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Smith & Nephew, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSmith & Nephew$5.81B2.01$263M$2.1612.40Bausch + Lomb$4.79B0.99-$317M-$0.91-14.72 Does the media prefer SNN or BLCO? In the previous week, Bausch + Lomb had 2 more articles in the media than Smith & Nephew. MarketBeat recorded 8 mentions for Bausch + Lomb and 6 mentions for Smith & Nephew. Smith & Nephew's average media sentiment score of 1.70 beat Bausch + Lomb's score of 0.17 indicating that Smith & Nephew is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Smith & Nephew 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Bausch + Lomb 1 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummarySmith & Nephew beats Bausch + Lomb on 12 of the 18 factors compared between the two stocks. Get Bausch + Lomb News Delivered to You Automatically Sign up to receive the latest news and ratings for BLCO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BLCO vs. The Competition Export to ExcelMetricBausch + LombOphthalmic goods IndustryMedical SectorNYSE ExchangeMarket Cap$4.52B$10.88B$5.35B$18.67BDividend YieldN/A0.96%5.44%4.16%P/E Ratio-14.0735.2921.9331.63Price / Sales0.942.73396.6327.49Price / Cash8.4114.5338.2017.53Price / Book0.692.296.744.36Net Income-$317M$224.27M$3.21B$1.02B7 Day Performance6.07%2.81%5.31%1.58%1 Month Performance-19.54%-16.31%-6.34%-7.33%1 Year Performance-14.09%-24.89%16.32%1.81% Bausch + Lomb Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BLCOBausch + Lomb3.9198 of 5 stars$13.51+6.1%$18.82+39.3%-13.8%$4.77B$4.79B-14.8512,500Upcoming EarningsGap UpSNNSmith & Nephew2.4922 of 5 stars$25.71-0.8%$27.00+5.0%+7.0%$11.24B$5.81B11.9020,100SOLVSolventum1.5821 of 5 stars$64.08-3.3%$79.86+24.6%+3.9%$11.09B$8.25B23.3022,000PENPenumbra4.0681 of 5 stars$270.53-2.5%$293.93+8.7%+35.2%$10.47B$1.19B795.683,900Earnings ReportAnalyst ForecastNews CoverageGap UpSTVNStevanato Group1.4106 of 5 stars€21.65-1.0%N/A-19.7%$6.56B$1.10B46.064,650Analyst UpgradeGKOSGlaukos4.6161 of 5 stars$88.17-2.3%$156.17+77.1%-8.3%$4.99B$383.48M-30.72780Upcoming EarningsNARIInari Medical0.652 of 5 stars$79.97flat$68.00-15.0%N/A$4.68B$493.63M-59.24800Upcoming EarningsPositive NewsINSPInspire Medical Systems4.6729 of 5 stars$144.74-3.6%$218.90+51.2%-36.6%$4.31B$802.80M83.67760Analyst ForecastNews CoveragePositive NewsSLNOSoleno Therapeutics4.8052 of 5 stars$68.93-1.5%$99.63+44.5%+80.4%$3.16BN/A-20.7630Analyst ForecastPositive NewsIRTCiRhythm Technologies1.0467 of 5 stars$98.63-2.3%$119.73+21.4%-11.8%$3.10B$591.84M-27.101,790Upcoming EarningsTMDXTransMedics Group2.6679 of 5 stars$87.72-0.6%$122.70+39.9%+1.9%$2.97B$441.54M93.32210Upcoming EarningsAnalyst Forecast Related Companies and Tools Related Companies Smith & Nephew Competitors Solventum Competitors Penumbra Competitors Stevanato Group Competitors Glaukos Competitors Inari Medical Competitors Inspire Medical Systems Competitors Soleno Therapeutics Competitors iRhythm Technologies Competitors TransMedics Group Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:BLCO) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe Collapse Is Already HereWhen a system is about to fail, those trained to spot it often notice before anyone else. Tim Plaehn flew high...Investors Alley | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bausch + Lomb Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bausch + Lomb With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.